Imperial College London
Portrait Picture

ProfessorAndrewBush

Faculty of Medicine, National Heart & Lung Institute

Professor of Paediatric Respirology
 
 
 
//

Contact

 

+44 (0)20 7352 8121 ext 2255a.bush

 
 
//

Location

 

Chelsea WingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Smith:2017:femsle/fnx121,
author = {Smith, WD and Bardin, E and Cameron, L and Edmondson, CL and Farrant, KV and Martin, I and Murphy, RA and Soren, O and Turnbull, AR and Wierre-Gore, N and Alton, EW and Bundy, JG and Bush, A and Connett, GJ and Faust, SN and Filloux, A and Freemont, PS and Jones, AL and Takats, Z and Webb, JS and Williams, HD and Davies, JC},
doi = {femsle/fnx121},
journal = {FEMS Microbiology Letters},
title = {Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis},
url = {http://dx.doi.org/10.1093/femsle/fnx121},
volume = {364},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Pseudomonas aeruginosa opportunistically infects the airways of patients with cystic fibrosis and causes significant morbidity and mortality. Initial infection can often be eradicated though requires prompt detection and adequate treatment. Intermittent and then chronic infection occurs in the majority of patients. Better detection of P. aeruginosa infection using biomarkers may enable more successful eradication before chronic infection is established. In chronic infection P. aeruginosa adapts to avoid immune clearance and resist antibiotics via efflux pumps, β-lactamase expression, reduced porins and switching to a biofilm lifestyle. The optimal treatment strategies for P. aeruginosa infection are still being established, and new antibiotic formulations such as liposomal amikacin, fosfomycin in combination with tobramycin and inhaled levofloxacin are being explored. Novel agents such as the alginate oligosaccharide OligoG, cysteamine, bacteriophage, nitric oxide, garlic oil and gallium may be useful as anti-pseudomonal strategies, and immunotherapy to prevent infection may have a role in the future. New treatments that target the primary defect in cystic fibrosis, recently licensed for use, have been associated with a fall in P. aeruginosa infection prevalence. Understanding the mechanisms for this could add further strategies for treating P. aeruginosa in future.
AU  - Smith,WD
AU  - Bardin,E
AU  - Cameron,L
AU  - Edmondson,CL
AU  - Farrant,KV
AU  - Martin,I
AU  - Murphy,RA
AU  - Soren,O
AU  - Turnbull,AR
AU  - Wierre-Gore,N
AU  - Alton,EW
AU  - Bundy,JG
AU  - Bush,A
AU  - Connett,GJ
AU  - Faust,SN
AU  - Filloux,A
AU  - Freemont,PS
AU  - Jones,AL
AU  - Takats,Z
AU  - Webb,JS
AU  - Williams,HD
AU  - Davies,JC
DO  - femsle/fnx121
PY  - 2017///
SN  - 0378-1097
TI  - Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
T2  - FEMS Microbiology Letters
UR  - http://dx.doi.org/10.1093/femsle/fnx121
VL  - 364
ER  -
Download